Avant Technologies and Ainnova Explore Integrating Early Detection of Dementia into AI-Powered Preventative Screening Platform
Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech are exploring the integration of early dementia detection into Ainnova's Vision AI platform. The companies are considering either licensing or acquiring a patented technology that uses AI algorithms and hardware for dementia detection through a 5-minute blood test.
The Vision AI platform currently employs 4 integrated algorithms to assess risks for cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease using retinal images, blood pressure, and lab test data. The system utilizes an automated, low-cost retinal imaging device for comprehensive preventive risk screening.
Avant Technologies (OTCQB: AVAI) e il suo partner in joint venture Ainnova Tech stanno valutando l'integrazione della rilevazione precoce della demenza nella piattaforma Vision AI di Ainnova. Le aziende stanno considerando di ottenere in licenza o acquisire una tecnologia brevettata che utilizza algoritmi di intelligenza artificiale e hardware per la diagnosi della demenza tramite un test del sangue di 5 minuti.
La piattaforma Vision AI attualmente impiega 4 algoritmi integrati per valutare i rischi di malattie cardiovascolari, diabete di tipo 2, fibrosi epatica e malattia renale cronica utilizzando immagini retiniche, pressione sanguigna e dati di analisi di laboratorio. Il sistema utilizza un dispositivo automatizzato a basso costo per l'imaging retinico, offrendo uno screening preventivo completo dei rischi.
Avant Technologies (OTCQB: AVAI) y su socio en joint venture Ainnova Tech están explorando la integración de la detección temprana de demencia en la plataforma Vision AI de Ainnova. Las compañías están considerando licenciar o adquirir una tecnología patentada que utiliza algoritmos de IA y hardware para detectar la demencia mediante un análisis de sangre de 5 minutos.
La plataforma Vision AI actualmente emplea 4 algoritmos integrados para evaluar riesgos de enfermedades cardiovasculares, diabetes tipo 2, fibrosis hepática y enfermedad renal crónica utilizando imágenes retinianas, presión arterial y datos de pruebas de laboratorio. El sistema utiliza un dispositivo automatizado y de bajo costo para imágenes retinianas, ofreciendo un examen preventivo integral de riesgos.
Avant Technologies (OTCQB: AVAI)와 합작 파트너 Ainnova Tech는 Ainnova의 Vision AI 플랫폼에 조기 치매 감지 기능을 통합하는 방안을 모색 중입니다. 두 회사는 5분 혈액 검사로 치매를 감지하는 AI 알고리즘과 하드웨어를 활용한 특허 기술을 라이선스하거나 인수하는 것을 검토하고 있습니다.
Vision AI 플랫폼은 현재 망막 이미지, 혈압, 실험실 검사 데이터를 이용해 심혈관 질환, 제2형 당뇨병, 간 섬유증, 만성 신장 질환 위험을 평가하는 4가지 통합 알고리즘을 사용하고 있습니다. 이 시스템은 자동화된 저비용 망막 촬영 장치를 활용하여 포괄적인 예방 위험 검사를 제공합니다.
Avant Technologies (OTCQB : AVAI) et son partenaire en coentreprise Ainnova Tech explorent l’intégration de la détection précoce de la démence dans la plateforme Vision AI d’Ainnova. Les entreprises envisagent soit de concéder sous licence, soit d’acquérir une technologie brevetée utilisant des algorithmes d’IA et du matériel pour détecter la démence via un test sanguin de 5 minutes.
La plateforme Vision AI utilise actuellement 4 algorithmes intégrés pour évaluer les risques de maladies cardiovasculaires, diabète de type 2, fibrose hépatique et maladie rénale chronique à partir d’images rétiniennes, de la tension artérielle et des données d’analyses de laboratoire. Le système utilise un dispositif automatisé et peu coûteux d’imagerie rétinienne pour un dépistage préventif complet des risques.
Avant Technologies (OTCQB: AVAI) und ihr Joint-Venture-Partner Ainnova Tech prüfen die Integration der Früherkennung von Demenz in Ainnovas Vision AI-Plattform. Die Unternehmen erwägen entweder die Lizenzierung oder den Erwerb einer patentierten Technologie, die KI-Algorithmen und Hardware zur Demenz-Erkennung mittels eines 5-minütigen Bluttests einsetzt.
Die Vision AI-Plattform verwendet derzeit 4 integrierte Algorithmen zur Bewertung von Risiken für Herz-Kreislauf-Erkrankungen, Typ-2-Diabetes, Leberfibrose und chronische Nierenerkrankungen anhand von Netzhautbildern, Blutdruck und Laborwerten. Das System nutzt ein automatisiertes, kostengünstiges Netzhaut-Bildgebungsgerät für ein umfassendes präventives Risikoscreening.
- Potential expansion into dementia detection market through patented technology
- Existing comprehensive platform already screens for multiple major diseases
- Technology offers rapid results through 5-minute blood test
- Low-cost, automated screening system enhances accessibility
- Technology acquisition/licensing still in exploratory phase with no definitive agreement
- Integration timeline and costs not disclosed
- No mention of regulatory approvals or clinical validation status
Currently, the Company has identified a promising patented early disease detection technology specializing in the early detection of dementia and is exploring its options to either license the technology globally or potentially acquire the technology altogether. The patented technology combines AI algorithms and hardware based on a 5-minute blood test. Adding the early detection of dementia would expand the offerings in the Company's technology portfolio and enhance the broader vision of the partnership between Avant and Ainnova.
The success of the Company's preventative screening platform involves the deployment of an automated, low-cost retinal imaging device integrated with the Vision AI platform to deliver comprehensive preventive risk screening. Presently, from just two retinal images, blood pressure and some lab test information, the Company's system uses 4 integrated algorithms to assess risks for: (i) cardiovascular disease (CVD), (ii) type 2 diabetes, (iii) liver fibrosis, and (iv) chronic kidney disease (CKD).
Vinicio Vargas, Chief Executive Officer at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp., said of the potential expansion of its technology portfolio, "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, with the ambition of reaching millions of patients globally in the coming years. Adding the early detection of dementia that this patented technology presents us, would go a long way to making us a leader in the industry of early disease detection."
About Ainnova Tech, Inc.
Ainnova is a
About Avant Technologies, Inc.
Avant Technologies, Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc. info@avanttechnologies.com
Video - https://mma.prnewswire.com/media/2696590/Avant_Technologies.mp4
Logo - https://mma.prnewswire.com/media/2370694/5338617/Avant_Technologies.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-ainnova-explore-integrating-early-detection-of-dementia-into-ai-powered-preventative-screening-platform-302465664.html
SOURCE Avant Technologies Inc.
FAQ
What diseases can Avant Technologies' (AVAI) Vision AI platform currently detect?
How does AVAI's new dementia detection technology work?
What is the partnership between Avant Technologies (AVAI) and Ainnova Tech?
How does Avant Technologies' (AVAI) Vision AI screening system work?
